PL2344677T3 - Sposoby i kompozycje do diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego - Google Patents

Sposoby i kompozycje do diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego

Info

Publication number
PL2344677T3
PL2344677T3 PL09804308T PL09804308T PL2344677T3 PL 2344677 T3 PL2344677 T3 PL 2344677T3 PL 09804308 T PL09804308 T PL 09804308T PL 09804308 T PL09804308 T PL 09804308T PL 2344677 T3 PL2344677 T3 PL 2344677T3
Authority
PL
Poland
Prior art keywords
diagnosis
compositions
treatment
methods
multiple sclerosis
Prior art date
Application number
PL09804308T
Other languages
English (en)
Inventor
Alasdair J. Coles
Joanne L. Jones
Alastair Compston
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of PL2344677T3 publication Critical patent/PL2344677T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1075Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
PL09804308T 2008-10-08 2009-10-08 Sposoby i kompozycje do diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego PL2344677T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19565808P 2008-10-08 2008-10-08
US19718708P 2008-10-24 2008-10-24
US19863108P 2008-11-07 2008-11-07
EP09804308.6A EP2344677B1 (en) 2008-10-08 2009-10-08 Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis

Publications (1)

Publication Number Publication Date
PL2344677T3 true PL2344677T3 (pl) 2017-11-30

Family

ID=42061141

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09804308T PL2344677T3 (pl) 2008-10-08 2009-10-08 Sposoby i kompozycje do diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego
PL17159235T PL3241910T3 (pl) 2008-10-08 2009-10-08 Sposoby diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17159235T PL3241910T3 (pl) 2008-10-08 2009-10-08 Sposoby diagnozowania i leczenia choroby autoimmunologicznej wtórnej względem stwardnienia rozsianego

Country Status (21)

Country Link
US (4) US20110229470A1 (pl)
EP (2) EP2344677B1 (pl)
JP (2) JP5856481B2 (pl)
KR (2) KR101825457B1 (pl)
CN (1) CN102245783B (pl)
AU (1) AU2009302117B2 (pl)
BR (1) BRPI0920546B1 (pl)
CA (1) CA2740077A1 (pl)
CY (1) CY1119513T1 (pl)
DK (1) DK2344677T3 (pl)
ES (2) ES2784830T3 (pl)
HR (1) HRP20171023T1 (pl)
HU (1) HUE035208T2 (pl)
IL (1) IL212069A (pl)
LT (1) LT2344677T (pl)
MX (1) MX336835B (pl)
PL (2) PL2344677T3 (pl)
PT (2) PT2344677T (pl)
RU (1) RU2563521C2 (pl)
SI (1) SI2344677T1 (pl)
WO (1) WO2010041149A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029501A2 (pt) 2011-05-16 2017-01-24 Genzyme Corp indução de tolerância imune usando metotrexato
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
CN115252789A (zh) 2016-03-10 2022-11-01 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
US20190187141A1 (en) * 2016-07-19 2019-06-20 Arete Discoveries, Inc. Biomarkers for Detection and Treatment of Mast Cell Activity-Associated Disorders
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US11672092B2 (en) * 2019-11-06 2023-06-06 Steiner Enterprises Modular electrical distribution system for vehicles
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
JP2024520906A (ja) * 2021-05-13 2024-05-27 ジェンザイム・コーポレーション リンパ球除去療法後の二次的自己免疫に関する新規予測バイオマーカー
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
WO2025199539A2 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions for demethylation of bard1 and methods of use thereof for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6351720B1 (en) 1997-10-24 2002-02-26 Mitsubishi Heavy Industries, Ltd. Trolley camera position detecting apparatus
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6045501A (en) * 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
KR20040049845A (ko) 2001-09-04 2004-06-12 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 카스파제-8 결합 단백질, 이의 제조 및 용도
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
US20030124127A1 (en) 2001-12-06 2003-07-03 Lijun Yang Targeting leukemia cells
CA2487133A1 (en) 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
MXPA05010035A (es) * 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
CA2574848A1 (en) * 2004-08-05 2006-12-21 Wyeth Antagonizing interleukin-21 receptor activity
AU2006340750B2 (en) * 2005-11-28 2013-03-07 Zymogenetics, Inc. IL-21 antagonists

Also Published As

Publication number Publication date
JP5856481B2 (ja) 2016-02-09
LT2344677T (lt) 2017-09-25
CA2740077A1 (en) 2010-04-15
JP2014195462A (ja) 2014-10-16
CN102245783B (zh) 2015-12-16
US20220349899A1 (en) 2022-11-03
WO2010041149A2 (en) 2010-04-15
MX336835B (es) 2016-02-03
HRP20171023T1 (hr) 2017-10-06
SI2344677T1 (sl) 2017-10-30
DK2344677T3 (en) 2017-07-24
WO2010041149A3 (en) 2010-09-30
US20200191799A1 (en) 2020-06-18
EP3241910B1 (en) 2020-01-08
KR101825457B1 (ko) 2018-02-05
EP2344677A2 (en) 2011-07-20
RU2563521C2 (ru) 2015-09-20
IL212069A0 (en) 2011-06-30
KR20110094276A (ko) 2011-08-23
KR101682730B1 (ko) 2016-12-05
IL212069A (en) 2016-04-21
US20160356788A1 (en) 2016-12-08
BRPI0920546B1 (pt) 2021-08-10
US10598670B2 (en) 2020-03-24
US20110229470A1 (en) 2011-09-22
US11243211B2 (en) 2022-02-08
HUE035208T2 (hu) 2018-05-02
RU2011118477A (ru) 2012-11-20
CY1119513T1 (el) 2018-03-07
PT3241910T (pt) 2020-04-07
HK1246364A1 (en) 2018-09-07
CN102245783A (zh) 2011-11-16
KR20160140984A (ko) 2016-12-07
AU2009302117B2 (en) 2016-07-28
ES2632213T3 (es) 2017-09-11
AU2009302117A1 (en) 2010-04-15
ES2784830T3 (es) 2020-10-01
EP2344677B1 (en) 2017-04-05
MX2011003730A (es) 2011-07-28
PL3241910T3 (pl) 2020-10-19
PT2344677T (pt) 2017-07-13
EP3241910A1 (en) 2017-11-08
BRPI0920546A2 (pt) 2020-06-02
JP2012504954A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
IL212069A0 (en) Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
IL267014A (en) Preparations and methods for the treatment of autoimmune diseases and other diseases
IL225519A0 (en) Effective preparations and methods for the treatment and diagnosis of inflammatory bowel disease
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
ZA201100974B (en) Treatment of autoimmune and inflammatory disease
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
ZA201105472B (en) Methods and compositions for diagnosis and treatment of cancer
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
IL236516A0 (en) Methods and preparations for the diagnosis and treatment of cancer
IL216993A0 (en) Compositions and methods for treatment of multiple sclerosis
PT2621520E (pt) Composições de colagenase g e colagenase h para o tratamento de doenças que envolvem alterações de colagénio
EP2633054A4 (en) NEW COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES
EP2459206A4 (en) METHODS OF TREATMENT USING THYMUS-BASED COMPOSITIONS
EP2405747A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
EP2147013A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND FEARING
IL217133A0 (en) Diagnosis and treatment of autoimmune demyelinating diseases
EP2262509A4 (en) GALLIUM COMPOUNDS AND METHOD OF USE FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
HU0900199D0 (en) Diagnosis of gluten-induced autoimmune diseases
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
GB201018362D0 (en) Treatment of dupuytren's disease